Highline Wealth Partners’s ImmunityBio IBRX Stock Holding History

Highline Wealth Partners’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,000	Closed	-$15.3K	–	1453
2026 Q1	$15.3K	Buy	+2,000	New	+$13.7K	﹤0.01%	352

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Highline Wealth Partners's IBRX Position: Q2 2026 in Review

Highline Wealth Partners sold out of ImmunityBio (IBRX) in Q2 2026, closing a stake of 2,000 shares — an estimated $15.3K sold.

Highline Wealth Partners first reported a position in IBRX in Q1 2026 and held it in 1 quarter. The position peaked at $15.3K in Q1 2026. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Highline Wealth Partners reported no remaining ImmunityBio position as of Q2 2026 after selling out during the quarter.
Highline Wealth Partners sold 2,000 ImmunityBio shares in Q2 2026, an estimated $15.3K.
Highline Wealth Partners first reported a position in ImmunityBio in Q1 2026 and held it in 1 quarter.
Highline Wealth Partners's ImmunityBio position peaked at $15.3K in Q1 2026.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Highline Wealth Partners's 13F filing for Q2 2026, filed 15 Jul 2026.